University closes PTSD studies after complaints from drug regulator
BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i3891 (Published 12 July 2016) Cite this as: BMJ 2016;354:i3891- Owen Dyer
- Montreal
Eight studies into an experimental drug to treat post traumatic stress disorder (PTSD) have been halted by New York University (NYU) and their principal investigator has resigned after a letter from the US Food and Drug Administration (FDA) warned that lapses in the conduct of the research jeopardized “subject safety and welfare, and raised concerns about the validity and integrity of the data collected at [the] site.”
The studies, sponsored by Pfizer, were trials of a fatty acid amide hydrolase (FAAH) inhibitor, a drug with effects on cannabinoid receptors, as a potential treatment for distress in patients with traumatic memories.
The FDA warning came in a …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.